U.S., July 28 -- ClinicalTrials.gov registry received information related to the study (NCT07728708) titled 'Effects of Axatilimab on Skin in Chronic Graft-versus-Host Disease' on July 22.
Brief Summary: Chronic graft-versus-host disease (cGVHD) is a condition that can develop after a stem cell transplant. It occurs when donor immune cells attack the body's tissues. In many people, cGVHD affects the skin, causing inflammation, thickening, and scarring that can limit movement and reduce quality of life.
Axatilimab is a medicine approved by the U.S. Food and Drug Administration (FDA) to treat adults with cGVHD after at least two previous treatments have not worked well enough. Although axatilimab can improve cGVHD, researchers do not fully ...